Compare Novo Nordisk A/S (NVO) vs Ovintiv Inc. (DE) (OVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ovintiv Inc. (DE) — how do they compare? Novo Nordisk A/S trades at $38.6 (market cap $165.31B), while Ovintiv Inc. (DE) trades at $63.88 (market cap $17.53B). The key difference: Novo Nordisk A/S is far larger — about 9.4× Ovintiv Inc. (DE)'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Ovintiv Inc. (DE) for 1 Days on average.
| NVO | OVV | |
|---|---|---|
Market Cap | $165.31B | $17.53B |
Volume | 11,432,838 | 3,002,714 |
Sector | Health | Energy |
52-Week High | $63.98 | $66.97 |
52-Week Low | $35.29 | $35.97 |
Typical Hold Time | 116 Days | 1 Days |
Enterprise Value | $179.56B | $21.86B |
Dividend Yield | 4.71% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ovintiv Inc. (DE)
Ovintiv explores for and produces oil and natural gas in North America. Its operations are concentrated in major U.S. and Canadian resource basins.
Read more on OVV →
